Pfizer CEO Albert Bourla has revealed that he recently dined with health secretary nominee and vaccine skeptic Robert F.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Pfizer CEO Albert Bourla said there are "opportunities that probably outweigh the risks" of the Trump administration's "radical" changes.

CEO Albert Bourla told investors Tuesday morning that he is “cautiously optimistic” about working with Robert F. Kennedy Jr., ...

Pfizer’s chief executive said he was “disappointed” with Robert F Kennedy Jr’s refusal to disavow the debunked link between vaccines and autism, even as he expressed confidence that the Trump ...

CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing transformative changes.’ ...

众所周知，在特朗普第一个任期的末尾，曾推动180亿美元的“快速行动”计划，帮助辉瑞快速推出新冠疫苗和治疗药物。由于辉瑞公布积极疫苗数据恰逢2020年美国大选刚结束之际，耿耿于怀的特朗普一直指责“医药集团暗助拜登”。

在最近的摩根大通医疗保健会议上，美国制药巨头辉瑞的首席执行官Albert ...

In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...

The pharma executive is optimistic about the new US administration but is also realistic about the risks that come with "radical change." ...

Pfizer CEO has met with the new administration and believes Trump and RFK Jr. are going to be net positives for the health sector.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...